Acute allergic reaction: Difference between revisions
| (34 intermediate revisions by 8 users not shown) | |||
| Line 1: | Line 1: | ||
== | ==Background== | ||
*Similar to [[Anaphylaxis]] but does not meet all the requirements (i.e. just skin manifestations) | |||
*Type I [[Hypersensitivity Reaction|hypersensitivity reaction]] | |||
== | ==Clinical Features== | ||
[[ | [[File:Hives2010.jpg|thumbnail|Raised urticaria]] | ||
*Presentation can be delayed | |||
[[Category: | ==Differential Diagnosis== | ||
[[Category: | {{Acute Allergic DDX}} | ||
==Evaluation== | |||
*Clinical | |||
**Rule out [[Anaphylaxis]] | |||
**Difficult to differentiate from [[Angioedema]] | |||
==Management== | |||
#[[H1 antagonist]]: [[Diphenhydramine]] 50mg IV/IM/PO | |||
#*H1 antagonists with low sedating activity, such as fexofenadine, loratadine, cetirizine, are preferred over [[diphenhydramine]] and hydroxyzine when appropriate<ref>[Guideline] Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009 Oct. 64(10):1427-43</ref> | |||
#[[H2 antagonist]]: [[Famotidine]] 40mg '''OR''' [[ranitidine]] 150mg IV/IM/PO | |||
#*Improves urticaria but not angioedema at 2 hours<ref>Lin, RY et al. Improved Outcomes in Patients With Acute Allergic Syndromes Who Are Treated With Combined H1 and H2 Antagonists. Annals of Emergency Medicine. 36:5 NOVEMBER 2000.</ref> | |||
#Consider [[corticosteroid]]: [[methylprednisolone]] 125mg IV/IM '''OR''' [[prednisone]] 60mg PO | |||
#*Continue steroid burst if outpatient (40mg [[prednisone]] PO x 5 days) | |||
==Disposition== | |||
*Consider brief observation in the ED for improvement of symptoms | |||
==See Also== | |||
*[[Anaphylaxis]] | |||
*[[Chronic urticaria]] | |||
==References== | |||
<references/> | |||
[[Category:Critical Care]] | |||
[[Category:Dermatology]] | |||
Revision as of 15:52, 17 August 2019
Background
- Similar to Anaphylaxis but does not meet all the requirements (i.e. just skin manifestations)
- Type I hypersensitivity reaction
Clinical Features
- Presentation can be delayed
Differential Diagnosis
Acute allergic reaction
- Allergic reaction/urticaria
- Anaphylaxis
- Angioedema
- Anxiety attack
- Asthma exacerbation
- Carcinoid syndrome
- Cold urticaria
- Contrast induced allergic reaction
- Scombroid
- Shock
- Transfusion reaction
Evaluation
- Clinical
- Rule out Anaphylaxis
- Difficult to differentiate from Angioedema
Management
- H1 antagonist: Diphenhydramine 50mg IV/IM/PO
- H1 antagonists with low sedating activity, such as fexofenadine, loratadine, cetirizine, are preferred over diphenhydramine and hydroxyzine when appropriate[1]
- H2 antagonist: Famotidine 40mg OR ranitidine 150mg IV/IM/PO
- Improves urticaria but not angioedema at 2 hours[2]
- Consider corticosteroid: methylprednisolone 125mg IV/IM OR prednisone 60mg PO
- Continue steroid burst if outpatient (40mg prednisone PO x 5 days)
Disposition
- Consider brief observation in the ED for improvement of symptoms
See Also
References
- ↑ [Guideline] Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009 Oct. 64(10):1427-43
- ↑ Lin, RY et al. Improved Outcomes in Patients With Acute Allergic Syndromes Who Are Treated With Combined H1 and H2 Antagonists. Annals of Emergency Medicine. 36:5 NOVEMBER 2000.